EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.
about
EGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell LineA focused compound screen highlights the significance of epidermal growth factor receptor signalling in chordoma pathogenesis.A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of gliomaAnti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.Incomplete target neutralization by the anti-cancer antibody rilotumumab.Exploiting receptor tyrosine kinase co-activation for cancer therapy.Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma.EGFRvIII: the promiscuous mutationInterleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.Genomic copy number gains of ErbB family members predict poor clinical outcomes in glioma patients.The power of the few.Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation.
P2860
Q28551853-86CDCC91-2640-4078-AD70-BF27F8A7969EQ33276173-A58B2CA3-5122-400E-A2F2-A9C28F6A6118Q33732661-A029E0B6-9634-431F-88FE-6BE4D9CF9541Q33734403-898D6683-C8FC-4E3A-A199-499B0B08C0A4Q33795137-A64A56EF-9C30-4DB1-8FB4-174A54B69701Q35804765-A4CE65A9-7202-4D70-A5A1-DB2A19B6AFDCQ37138513-3D4D5C8C-711B-4CAF-9E13-D2415CAF3434Q38906990-DC7CAF37-7EEF-4675-859D-CA7B72EF3916Q41098475-1D0F782C-569C-4D33-ABC5-7F5898D534D7Q42367951-F54135E6-26AD-4FC9-BE3E-901C5E82701EQ45074720-01CCC1FA-81DE-4CFB-8E77-0915A0511122Q46093038-2A77B445-D024-4607-B261-92B66A960979Q47097853-AC3DC117-1853-43BB-A725-ECE2948CB8B7Q47134822-F9F79067-F28B-4F6A-8CE2-BA22462AE011Q49359610-D45AA1D2-F46A-4363-A813-FC529161C9ACQ50100856-961A9B7C-0885-42E6-829F-6D4B3394A36CQ50324498-FCB541BA-D3DF-4382-8CC0-0E22110634A5
P2860
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
EGFRvIII-mediated transactivat ...... and therapeutic implications.
@en
type
label
EGFRvIII-mediated transactivat ...... and therapeutic implications.
@en
prefLabel
EGFRvIII-mediated transactivat ...... and therapeutic implications.
@en
P2093
P2860
P50
P356
P1433
P1476
EGFRvIII-mediated transactivat ...... m and therapeutic implications
@en
P2093
M Van Sinderen
V Dubljevic
P2860
P2888
P304
P356
10.1038/ONC.2014.448
P407
P577
2015-02-09T00:00:00Z
P5875
P6179
1016926114